Company Overview
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Recent Developments
- Dec 2025 Revenue of $1.00M (-82.5% YoY); net profit $-48.81M.
- Trailing 12 Months Year-on-year growth — revenue -82.5%.
- 5-Year Trend Long-term compounding — revenue CAGR -31.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -31.74% |
| 1 Year: | -82.52% |
Stock Price Performance
| 1 Year: | +701.48% |
| 6 Months: | +7.97% |
| 3 Months: | +66.67% |
| 1 Month: | -10.59% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)38.46 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -31.7% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | STTK Shattuck Labs, Inc. PHARMA | 6.50 | -14.77 | $652.36M | 0.00% | -61.34% | -39.21% | -31.74% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 1.78M | 2.98M | 3.18M | 2.44M | 2.27M | -4.23M | 1.90M | 0 | 50.00K | 212.00K | 57.00K | 200.00K | 686.00K | 1.11M | 1.61M | 3.00M | 0 | 0 | 1.00M | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.39M | 13.03M | 11.72M | 13.37M | 15.54M |
| Operating Income | - | - | -7.53M | -6.76M | -6.32M | -11.84M | -12.42M | -24.51M | -17.58M | -24.17M | -27.66M | -25.23M | -21.66M | -22.75M | -28.60M | -20.04M | -22.96M | -17.92M | -14.39M | -13.03M | -10.72M | -13.37M | -15.54M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -13.45M | -12.10M | -9.80M | -12.46M | -14.65M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -13.70M | -12.46M | -10.06M | -12.59M | -14.77M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -3.45M | -5.88M | -7.28M | -6.55M | -6.21M | -11.83M | -11.81M | -23.60M | -17.41M | -24.53M | -27.37M | -24.64M | -20.72M | -21.35M | -27.54M | -18.50M | -21.55M | -16.68M | -13.70M | -12.46M | -10.06M | -12.59M | -14.77M |
| Diluted EPS | - | - | - | - | -0.81 | -1.54 | -0.28 | -0.56 | -0.41 | -0.58 | -0.65 | -0.58 | -0.49 | -0.50 | -0.65 | -0.37 | -0.42 | -0.33 | -0.27 | -0.24 | -0.14 | -0.12 | -0.13 |
| R&D Expense | - | - | 7.95M | 8.14M | 7.75M | 11.80M | 10.34M | 14.88M | 15.14M | 19.19M | 22.96M | 18.86M | 16.67M | 18.20M | 24.21M | 16.26M | 19.24M | 16.31M | 9.92M | 8.68M | 7.62M | - | 10.95M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 9.89M | 9.93M | 30.02M | 652.00K | 1.66M | 5.72M | 1.00M |
| Cost of Revenue | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | 103.98M | 93.61M | 86.29M | 52.51M |
| Operating Income | -25.07M | -36.93M | -45.27M | -103.33M | -91.96M | -80.57M | -51.51M |
| EBITDA | - | - | - | -100.26M | -87.92M | -76.74M | -47.82M |
| Interest Expense | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | -101.94M | -87.30M | -75.41M | -48.81M |
| Tax Provision | - | - | - | - | - | - | - |
| Net Income | -23.98M | -36.60M | -44.97M | -101.94M | -87.30M | -75.41M | -48.81M |
| Diluted EPS | - | -2.36 | -1.07 | -2.41 | -2.05 | -1.49 | -0.70 |
| R&D Expense | 29.22M | 37.48M | 56.56M | 82.90M | 74.31M | 67.21M | 35.27M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 44.97M | 348.99M | - | 205.32M | 159.56M | 91.05M | 91.03M |
| Current Assets | - | - | - | - | 184.58M | 143.22M | 79.22M | 82.47M |
| Cash & Equivalents | - | 7.01M | 157.90M | - | 47.38M | 125.63M | 57.39M | 54.19M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - |
| Total Liabilities | - | 30.45M | 39.13M | - | 29.17M | 14.86M | 11.42M | 8.64M |
| Current Liabilities | - | 19.98M | 16.83M | - | 24.96M | 11.45M | 8.92M | 7.05M |
| Long Term Debt | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | 4.90M | 4.20M | 3.41M | 2.42M |
| Total Equity | -11.08M | -34.55M | 309.86M | - | 176.16M | 144.71M | 79.63M | 82.39M |
| Shares Outstanding | - | - | - | - | 42.39M | 47.26M | 47.71M | 63.28M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -20.98M | -33.66M | - | -94.50M | -81.23M | -60.52M | -39.88M |
| Investing Cash Flow | -3.59M | -146.32M | - | 49.44M | 110.86M | -8.51M | -7.89M |
| Financing Cash Flow | -64.00K | 330.87M | - | 171.00K | 48.62M | 787.00K | 44.57M |
| Capital Expenditure | -470.00K | -727.00K | - | -11.61M | -407.00K | -59.00K | -71.00K |
| Free Cash Flow | -21.45M | -34.39M | - | -106.11M | -81.64M | -60.57M | -39.95M |
| Net Change in Cash | - | - | - | -44.89M | 78.25M | -68.24M | -3.19M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | -253.5% | -371.8% | -150.8% | -15,848.0% | -5,549.6% | -1,408.3% | -5,150.8% |
| Net Margin % | -242.6% | -368.5% | -149.8% | -15,635.7% | -5,268.4% | -1,318.1% | -4,880.9% |
| ROE % | 69.4% | -11.8% | - | -57.9% | -60.3% | -94.7% | -59.2% |
| ROCE % | -100.3% | -11.1% | - | -57.3% | -62.1% | -98.1% | -61.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | T. Rowe Price Investment Management, Inc. | 13.38% | 13.43M | $80.73M |
| 2 | Adage Capital Partners GP L.L.C. | 8.09% | 8.12M | $48.81M |
| 3 | Redmile Group, LLC | 6.87% | 6.89M | $41.42M |
| 4 | Orbimed Advisors LLC. | 6.28% | 6.31M | $37.90M |
| 5 | Prosight Management, Lp | 5.94% | 5.96M | $35.81M |
| 6 | Blackrock Inc. | 3.92% | 3.94M | $23.65M |
| 7 | Frazier Life Sciences Management, L.P. | 3.74% | 3.75M | $22.54M |
| 8 | Nextbio Capital Management LP | 3.71% | 3.73M | $22.40M |
| 9 | Deep Track Capital, Lp | 3.69% | 3.71M | $22.28M |
| 10 | Vanguard Capital Management LLC | 3.20% | 3.21M | $19.28M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for STTK
Liquidity Mapping Around (STTK) Price Events - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNd2lCRm1xdTExN2VBc2ZINVU1aXJfLW1vaktNNW1YbUplNEdaMXNVb3U5SjdaM0dVQjRka0V6R3VNMHdsaU1tWWlva081OFcwdTZKcUs5NVY4M0hlVzVoUllWc1F5WXNFZVdBclBTVkd5SHFWcXB3aUhtOG4tV2h5LWV6UTQycWNNQlltdF…
Shattuck Labs, Inc. (STTK) is a Great Momentum Stock: Should You Buy? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxOdmN5Skdmc1pqZnM0OUprd2dkRURGdzdpMlBKeENsY1g0RldNbng0bXFCaWZKNTluTDVQbmsybWFWQjR4enU3eURoMWRDSExkTTBQS1FnSkluVHZmR1Q5UzluQUF3R3Q4ZmYyNjFTZWJtbnZRWGRpZTY5REJnbDRPMXF4YU1YZ2QzeTdOSE…
$STTK stock is down 12% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQMGxENnlhV0lQbVExSFVxT1FlMkFJOTN4a09Oa2ZCaFczbjY5bWZ6bC04UkVCdFc3b0dkSXhRUk9QaWtaZlJ0aGhrd2VQQVN5clc3eU1HZFVEcEJXZlRwUzJibEYzZUk5cjVFWFQwcHRNN2tkVnpPd1JFT0l5d0EtWlNZRlVQSm9hVFVGd3…
SHATTUCK LABS STOCK : BIG PRICE RECOVERY | STTK STOCK Darpa Autonomous Drone Swarms (RwCs7APen5) - Mshale
<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE5pRmNleGotLV9vNWVrUWFSM2U0RVpPTE9OQmR5cklKYmZtdV9aaUUtSzkxU25ZSUl6bzJ1TVdNRUxtREtrQUNNOXBJRUx5UjRuUVFGdTQwQktnQVhHVlpsNA?oc=5" target="_blank">SHATTUCK LABS STOCK : BIG PRICE RECOV…
Inside Shattuck Labs' June 8 webcast on experimental inflammatory antibody - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQY0hDcUl0TllnUFBocXVnWTl3NVJLTlN0TVU0LVpCVWxtUUhobGVYcEQ4QjQ5UTlHd0hpNnVuWTNSbzMxUEFGLWN0VnItY2ZXek05akhpcjdpT0VndU8wTnQ4VkJ0ZC14dU84a05UM2ZmZmVFQVNuQWMyWDF3N19HdG1vRDFRNWFxUkpybG…
Shattuck Labs: A Receptor-Side Bet On The TL1A Boom - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxPWFl0MW90NTczVy1tZ0kxcElLbEdkLWlKd2JuS3BJWExSTWJyYTh2cExkX1BVUDVCS2N3T0xfX2ZydWdsemlESGNMSGpnN3VJWU1nWmRrZnpDdi1JcW93Qllna3BlMVE3amZadGlMWFd6SWRRVjNXaGpmT19WNDlKVXdVYnROUTRBd2pLST…
STTK — Frequently Asked Questions
What is the current share price of Shattuck Labs, Inc. (STTK)?
As of 2026-09-19 21:16 PDT, Shattuck Labs, Inc. (STTK) trades at $6.50 on NasdaqGS. Its 52-week range is $0.81 to $8.06.
What is the market capitalisation of STTK?
Shattuck Labs, Inc. (STTK) has a market capitalisation of $652.36M on NasdaqGS.
What is the P/E ratio of STTK?
STTK trades at a trailing price-to-earnings (P/E) ratio of -14.77. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.87.
What is the return on equity (ROE) of STTK?
STTK has a return on equity (ROE) of -39.21%. Its return on capital employed (ROCE) is -61.34%.
Is STTK a good stock to buy?
This page provides a data-driven analysis of Shattuck Labs, Inc. (STTK), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.